DICE Therapeutics, Inc. (DICE): Price and Financial Metrics
DICE Price/Volume Stats
| Current price | $47.55 | 52-week high | $47.90 |
| Prev. close | $47.52 | 52-week low | $15.08 |
| Day low | $47.46 | Volume | 4,332,900 |
| Day high | $47.83 | Avg. volume | 1,028,719 |
| 50-day MA | $42.55 | Dividend yield | N/A |
| 200-day MA | $34.31 | Market Cap | 2.27B |
DICE Stock Price Chart Interactive Chart >
DICE Therapeutics, Inc. (DICE) Company Bio
DICE Therapeutics, Inc., a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE, is designed to discover selective oral small molecules to modulate protein-protein interactions (PPIs) as effectively as systemic biologics. The company's lead therapeutic candidate is S011806, an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17, which is a validated drug target implicated in a various immunology indications. It is also developing oral therapeutic candidates targeting a4Ã7 integrin for the treatment of inflammatory bowel diseases, as well as targeting aVÃ1/aVÃ6 integrin for the treatment of idiopathic pulmonary fibrosis. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
Latest DICE News From Around the Web
Below are the latest news stories about DICE THERAPEUTICS INC that investors may wish to consider to help them evaluate DICE as an investment opportunity.
Lilly Announces Extension of Tender Offer to Acquire DICEEli Lilly and Company (NYSE: LLY) today announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding shares ("Shares") of common stock of DICE Therapeutics, Inc. (NASDAQ: DICE), for a purchase price of $48 per share in cash, without interest and less any applicable tax withholding. |
Cardlytics and Motorcar Parts of America Stock See Action From Activist InvestorsCAS Investment switched to an activist stance in digital-marketing company Cardlytics. Bison Capital increased its investment in retailer Motorcar Parts. |
Mergers Are Down, but These 2 Sectors Are BoomingTotal deal value worldwide is about $1.22 trillion year to date, according to data from London Stock Exchange Group. |
4 big deal reports: IBM to buy out Apptio for $5B, per media reportsHere is your Pro Recap of four head-turning deal dispatches you may have missed this week: IBM and Apptio merger rumors, Eli Lilly acquires Dice Therapeutics, Amazon's iRobot acquisition faces EU antitrust investigation, and Stratasys determines 3D Systems' offer not a 'Superior Proposal' to Desktop Metal agreement. InvestingPro subscribers got this news first. |
Why Dice Therapeutics Stock Bolted Higher This WeekThe big gain came after the company announced a $2.4 billion buyout agreement with industry heavyweight Eli Lilly (NYSE: LLY). Through this buyout, Lilly will add the experimental immunology medicines DC-806 and DC-853 to its pipeline. DC-806 is presently in midstage testing as a treatment for psoriasis. |
DICE Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | 44.62% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | N/A |
| 2023 | 0.00% |
| 2022 | 23.27% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...